Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Wang Website

Xin Wei Wang, Ph.D.

Selected Publications

1)  Roessler S, Budhu A, Wang XW.
Deciphering cancer heterogeneity: the biological space.
Front Cell Dev Biol. 2: 12, 2014.
Full Text Article. [Journal]
2)  Yamashita T, Kitao A, Matsui O, Hayashi T, Nio K, Kondo M, Ohno N, Miyati T, Okada H, Yamashita T, Mizukoshi E, Honda M, Nakanuma Y, Takamura H, Ohta T, Nakamoto Y, Yamamoto M, Takayama T, Arii S, Wang XW, Kaneko S.
Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma.
Hepatology. [Epub ahead of print], 2014.
3)  Parpart S, Roessler S, Dong F, Rao V, Takai A, Ji J, Qin L, Ye Q, Jia H, Tang Z, Wang XW.
Modulation of miR-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome.
Hepatology. [Epub ahead of print], 2014.
4)  Dang HT, Budhu A, Wang XW.
The origin of cancer stem cells.
J. Hepatol. [Epub ahead of print], 2014.
5)  Yamashita T, Wang XW.
Cancer stem cells in the development of liver cancer.
J. Clin. Invest. 123: 1911-8, 2013.
6)  Ji J, Yu L, Yu Z, Forgues M, Uenishi T, Kubo S, Wakasa K, Zhou J, Fan J, Tang ZY, Fu S, Zhu H, Jin JG, Sun HC, Wang XW.
Development of a miR-26 Companion Diagnostic Test for Adjuvant Interferon-alpha Therapy in Hepatocellular Carcinoma.
Int. J. Biol. Sci. 9: 303-12, 2013.
7)  Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, Yamashita T, Mizukoshi E, Ikeda H, Zen Y, Takamura H, Wang XW, Kaneko S.
Discrete nature of EpCAM(+) and CD90(+) cancer stem cells in human hepatocellular carcinoma.
Hepatology. 57: 1484-97, 2013.
8)  Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, Loffredo CA, Forgues M, Huang H, Xing XJ, Ren N, Dong QZ, Zhou HJ, Ren ZG, Zhao NQ, Wang XW, Tang ZY, Qin LX, Ye QH.
Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma.
Clin. Cancer Res. 19: 3944-3954, 2013.
9)  Henrich CJ, Budhu A, Yu Z, Evans JR, Goncharova EI, Ransom TT, Wang XW, McMahon JB.
High-throughput Screening for Identification of Inhibitors of EpCAM-Dependent Growth of Hepatocellular Carcinoma Cells.
Chem Biol Drug Des. 82: 131-9, 2013.
10)  Hsiao TH, Chen HI, Roessler S, Wang XW, Chen Y.
Identification of genomic functional hotspots with copy number alteration in liver cancer.
EURASIP J Bioinform Syst Biol. 2013: 14, 2013.
11)  Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, Karoly E, Qin L, Ye Q, Jia H, Fan J, Sun H, Tang Z, Wang XW.
Integrated Metabolite and Gene Expression Profiles Identify Lipid Biomarkers Associated with Progression of Hepatocellular Carcinoma and Patient Outcomes.
Gastroenterology. 144: 1066-1075, 2013.
12)  Ozdemir B, Abd-Almageed W, Roessler S, Wang XW.
iSubgraph: Integrative Genomics for Subgroup Discovery in Hepatocellular Carcinoma Using Graph Mining and Mixture Models.
PLoS ONE. 8: e78624, 2013.
13)  Parpart S, Wang XW.
microRNA Regulation and Its Consequences in Cancer.
Curr Pathobiol Rep. 1: 71-79, 2013.
14)  Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, Wang XW, Reid LM, Nakauchi H.
SALL4, a stem cell biomarker in liver cancers.
Hepatology. 57: 1469-83, 2013.
15)  Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M.
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.
Proc. Natl. Acad. Sci. U.S.A. 110: E1083-91, 2013.
16)  Xue W, Kitzing T, Roessler S, Zuber J, Krasnitz A, Schultz N, Revill K, Weissmueller S, Rappaport AR, Simon J, Zhang J, Luo W, Hicks J, Zender L, Wang XW, Powers S, Wigler M, Lowe SW.
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions.
Proc. Natl. Acad. Sci. U.S.A. 109: 8212-7, 2012.
17)  Budhu A, Wang XW.
At the cancer steering wheel: Defining key genomic drivers of liver cancer with next generation sequencing.
J Hepatol. 56: 1412-1414, 2012.
18)  Ji J, Wang XW.
Clinical Implications of Cancer Stem Cell Biology in Hepatocellular Carcinoma.
Semin Oncol. 39: 461-472, 2012.
19)  Zhao F, Hoechst B, Gamrekelashvili J, Ormandy LA, Voigtländer T, Wedemeyer H, Ylaya K, Wang XW, Hewitt SM, Manns MP, Korangy F, Greten TF.
Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses.
J. Immunol. 188: 6055-62, 2012.
20)  Ji J, Wang XW.
Identification of Cancer Stem Cell-Related MicroRNAs in Hepatocellular Carcinoma.
Methods Mol. Biol. 826: 163-75, 2012.
21)  Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HL, Ye QH, Qin LX, Tang ZY, He P, Hunter KW, Thorgeirsson SS, Meltzer PS, Wang XW.
Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival.
Gastroenterology. 142: 957-966.e12, 2012.
22)  Zhao Y, Schetter AJ, Yang GB, Nguyen G, Mathé EA, Li P, Cai H, Yu L, Liu F, Hang D, Yang H, Wang XW, Ke Y, Harris CC.
microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma.
Int. J. Cancer. 132: 2901-9, 2012.
23)  Wang XW, Heegaard NH, Orum H.
MicroRNAs in Liver Disease.
Gastroenterology. 142: 1431-1443, 2012.
24)  Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, Wang XW, Thorgeirsson SS, Lee JS.
Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma.
Hepatology. 55: 1443-52, 2012.
25)  Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, Zhao X, Andersen JB, Ye Q, Jia H, Qin L, Yamashita T, Woo HG, Kim YJ, Kaneko S, Tang Z, Thorgeirsson SS, Wang XW.
Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of mir-200c and EMT in intrahepatic cholangiocarcinoma.
Hepatology. 56: 1792-803, 2012.
26)  Budhu A, Wang XW.
Transforming the microenvironment: a trick of the metastatic cancer cell.
Cancer Cell. 22: 279-80, 2012.
27)  Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM, Tang Z, Sun Z, Harris CC, Thorgeirsson SS.
Association of TP53 Mutations with Stem Cell-Like Gene Expression and Survival of Patients with Hepatocellular Carcinoma.
Gastroenterology. 140: 1063-70, 2011.
28)  Budhu A, Wang XW.
MicroRNAs and Gastroenterological Cancers.
Drug Discov Today Dis Mech. 8: e95-e102, 2011.
29)  Kumar M, Zhao X, Wang XW.
Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?.
Cell Biosci. 1: 5, 2011.
30)  Oishi N, Wang XW.
Novel therapeutic strategies for targeting liver cancer stem cells.
Int. J. Biol. Sci. 7: 517-35, 2011.
31)  Budhu A, Wang XW.
Power play: Scoring our goals for liver cancer with better GWAS study design.
J Hepatol. 54: 823-4, 2011.
32)  Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, Ji J, Wang XW, Park SH, Cha YI, Gius D, Deng CX.
SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity.
Cancer Cell. 20: 487-99, 2011.
33)  Ji J, Yamashita T, Wang XW.
Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma.
Cell Biosci. 1: 4, 2011.
34)  Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, Wang XW.
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.
Cancer Res. 70: 10202-12, 2010.
35)  Ji J, Wang XW.
A Yin-Yang balancing act of the lin28/let-7 link in tumorigenesis.
J. Hepatol. 53: 974-5, 2010.
36)  Jiang W, Wang XW, Unger T, Forgues M, Kim JW, Hussain SP, Bowman E, Spillare EA, Lipsky MM, Meck JM, Cavalli LR, Haddad BR, Harris CC.
Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line.
Int J Cancer. 127: 1011-20, 2010.
37)  Nguyen GH, Schetter AJ, Chou DB, Bowman ED, Zhao R, Hawkes JE, Mathé EA, Kumamoto K, Zhao Y, Budhu A, Hagiwara N, Wang XW, Miyashita M, Casson AG, Harris CC.
Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma.
Clin. Cancer Res. 16: 5824-34, 2010.
38)  Ji J, Zhao L, Budhu A, Forgues M, Jia H, Qin L, Ye Q, Yu J, Shi X, Tang Z, Wang XW.
Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma.
J Hepatol. 52: 690-7, 2010.
39)  Yu L, Feng M, Kim H, Phung Y, Kleiner DE, Gores GJ, Qian M, Wang XW, Ho M.
Mesothelin as a potential therapeutic target in human cholangiocarcinoma.
J Cancer. 1: 141-9, 2010.
40)  Cairo S, Wang Y, de Reyniès A, Duroure K, Dahan J, Redon MJ, Fabre M, McClelland M, Wang XW, Croce CM, Buendia MA.
Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer.
Proc. Natl. Acad. Sci. U.S.A. 107: 20471-6, 2010.
41)  Budhu A, Ji J, Wang XW.
The Clinical Potential of MicroRNAs.
J Hematol Oncol. 3: 37, 2010.
42)  Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW.
EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features.
Gastroenterology. 136: 1012-1024.e4, 2009.
43)  Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, Qin LX, Yang W, Wang HY, Tang ZY, Croce CM, Wang XW.
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells.
Hepatology. 50: 472-80, 2009.
44)  Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson AG, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC.
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival.
Clin. Cancer Res. 15: 6192-200, 2009.
45)  Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW.
MicroRNA expression, survival, and response to interferon in liver cancer.
N. Engl. J. Med. 361: 1437-47, 2009.
46)  Ji J, Wang XW.
New kids on the block: Diagnostic and prognostic microRNAs in hepatocellular carcinoma.
Cancer Biol Ther. 8: 1686-93, 2009.
47)  Wang XW, Thorgeirsson SS.
Transcriptome analysis of liver cancer: ready for the clinic?.
J. Hepatol. 50: 1062-4, 2009.
48)  Dong F, Budhu AS, Wang XW.
Translating the metastasis paradigm from scientific theory to clinical oncology.
Clin. Cancer Res. 15: 2588-93, 2009.
49)  Yamashita T, Forgues M, Wang W, Kim JW, Ye QH, Jia HL, Budhu A, Zanetti KA, Chen Y, Qin LX, Tang ZY, Wang XW.
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.
Cancer Res. 68: 1451-61, 2008.
50)  Budhu A, Jia H, Forgues M, Liu C, Goldstein D, Lam A, Zanetti KA, Ye Q, Qin L, Croce CM, Tang Z, Wang XW.
Identification of metastasis-related microRNAs in hepatocellular carcinoma.
Hepatology. 47: 897-907, 2008.
51)  Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, Kim S, Xu X, Zheng Y, Chilton B, Jia R, Zheng ZM, Appella E, Wang XW, Ried T, Deng CX.
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.
Cancer Cell. 14: 312-23, 2008.
52)  Chen X, Yu B, Dong J, Gu Y, Chen L, Wu Q, Hou N, Liu J, Xu J, Jin R, Jin G, Yang X, Cao Y, Tan J, Zhu B, Shen J, Xu Z, Varticovski L, Wang XW.
A phase II clinical trial with cytotropic heterogeneous molecular lipids (CHML) for patients with hepatic malignancies.
Anticancer Res. 27: 1593-600, 2007.
53)  Yamashita T, Budhu A, Forgues M, Wang XW.
Activation of hepatic stem cell marker EpCAM by Wnt/beta-catenin signaling in hepatocellular carcinoma.
Cancer Res. 67: 10831-9, 2007.
54)  Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW.
An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma.
Oncogene. 26: 6361-71, 2007.
55)  Roessler S, Budhu A, Wang XW.
Future of molecular profiling of human hepatocellular carcinoma.
Future Oncol. 3: 429-439, 2007.
56)  Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, Liu YK, Sun HC, Wang L, Lu HZ, Shen F, Tang ZY, Wang XW.
Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma.
Clin. Cancer Res. 13: 1133-9, 2007.
57)  Budhu A, Chen Y, Kim JW, Forgues M, Valerie K, Harris CC, Wang XW.
Induction of a unique gene expression profile in primary human hepatocytes by hepatitis C virus core, NS3 and NS5A proteins.
Carcinogenesis. 28: 1552-60, 2007.
58)  Hussain SP, Schwank J, Staib F, Wang XW, Harris CC.
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Oncogene. 26: 2166-76, 2007.
59)  Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J, Shibata T, Sugimura H, Gemma A, Kudoh S, Wang XW, Harris CC.
Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.
J. Natl. Cancer Inst. 99: 1257-69, 2007.
60)  Yoshikawa H, Matsubara K, Zhou X, Okamura S, Kubo T, Murase Y, Shikauchi Y, Esteller M, Herman JG, Wang XW, Harris CC.
WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer.
Mol Biol Cell. 18: 4292-4303, 2007.
61)  Wu C, Budhu A, Chen S, Zhou X, Popescu NC, Valerie K, Wang XW.
Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocytes.
Mol. Med. 12: 47-53, 2006.
62)  Lamba JK, Chen X, Lan LB, Kim JW, Wei Wang X, Relling MV, Kazuto Y, Watkins PB, Strom S, Sun D, Schuetz JD, Schuetz EG.
Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans.
Pharmacogenet. Genomics. 16: 415-27, 2006.
63)  Lim MJ, Wang XW.
Nucleophosmin and human cancer.
Cancer Detect. Prev. 30: 481-90, 2006.
64)  Budhu A, Forgues M, Ye Q, Jia H, He P, Zanetti KA, Kammula US, Chen Y, Qin L, Tang Z, Wang XW.
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.
Cancer Cell. 10: 99-111, 2006.
65)  Spillare EA, Wang XW, von Kobbe C, Bohr VA, Hickson ID, Harris CC.
Redundancy of DNA helicases in p53-mediated apoptosis.
Oncogene. 25: 2119-23, 2006.
66)  Budhu A, Wang XW.
The role of cytokines in hepatocellular carcinoma.
J. Leukoc. Biol. 80: 1197-213, 2006.
67)  Budhu AS, Wang XW.
Loading and unloading: orchestrating centrosome duplication and spindle assembly by ran/crm1.
Cell Cycle. 4: 1508-12, 2005.
68)  Wang W, Budhu A, Forgues M, Wang XW.
Temporal and spatial control of nucleophosmin by the Ran/Crm1 complex in centrosome duplication.
Nat Cell Biol. 7: 823-30, 2005.
69)  Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A, Hamburger AW.
The ErbB3 binding protein Ebp1 suppresses AR mediated gene transcription and tumorigenesis of prostate cancer cells.
Proc Natl Acad Sci USA. 102: 9890-5, 2005.
70)  Budhu AS, Zipser B, Forgues M, Ye QH, Sun Z, Wang XW.
The molecular signature of metastases of human hepatocellular carcinoma.
Oncology. 69 (S1): 23-27, 2005.
71)  Staib F, Robles AI, Varticovski L, Wang XW, Zeeberg BR, Sirotin M, Zhurkin VB, Hofseth LJ, Hussain SP, Weinstein JN, Galle PR, Harris CC.
The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress.
Cancer Res. 65: 10255-64, 2005.
72)  Kim JW, Ye Q, Forgues M, Chen Y, Budhu A, Sime J, Hofseth LJ, Kaul R, Wang XW.
Cancer-associated molecular signature in the tissue samples of patients with cirrhosis.
Hepatology. 39: 518-27, 2004.
73)  Kim JW, Wang XW.
Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases?.
Carcinogenesis. 24: 363-9, 2003.
74)  Forgues M, Difilippantonio MJ, Linke SP, Ried T, Nagashima K, Feden J, Valerie K, Fukasawa K, Wang XW.
Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles.
Mol Cell Biol. 23: 5282-92, 2003.
75)  Linke SP, Sengupta S, Khabie N, Jeffries BA, Buchhop S, Miska S, Henning W, Pedeux R, Wang XW, Hofseth LJ, Yang Q, Garfield SH, Stürzbecher HW, Harris CC.
p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination.
Cancer Res. 63: 2596-605, 2003.
76)  Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW.
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning.
Nat Med. 9: 416-23, 2003.
77)  Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC.
TP53 and liver carcinogenesis.
Hum Mutat. 21: 201-16, 2003.
78)  Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T, Deng CX.
Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.
Mol. Cell. 3: 389-95, 1999.
79)  Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JH, Harris CC.
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway.
Genes Dev. 10: 1219-32, 1996.
80)  Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, Wang Z, Freidberg EC, Evans MK, Taffe BG.
p53 modulation of TFIIH-associated nucleotide excision repair activity.
Nat. Genet. 10: 188-95, 1995.
81)  Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC.
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3.
Proc. Natl. Acad. Sci. U.S.A. 91: 2230-4, 1994.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/19/2014.